Emerging drugs for the treatment of dry eye disease

Bibliography

• DEWS. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf 2007;5:75-92
   PubMed Web of Science ®Google Scholar
• Gipson IK, Hori Y, Argüeso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004;2(2):131-48
   PubMedGoogle Scholar
• Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2011;52(4):1930-7
   PubMed Web of Science ®Google Scholar
• Bron AJ, Sci FM, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf 2004;2:149-65
   PubMedGoogle Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012;130:90-100
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14:S102-6
   PubMedGoogle Scholar
• DEWS. The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international dry eye workshop (2007). Ocul Surf 2007;5:93-107
   PubMed Web of Science ®Google Scholar
• Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 2012;31(5):472-8
   PubMed Web of Science ®Google Scholar
• Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol 2010;21:310-16
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003;110:1412-19
   PubMed Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011;30(4):379-87
   PubMed Web of Science ®Google Scholar
• Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004;23:751-61
   PubMed Web of Science ®Google Scholar
• Foulks GN. Bak to Basics. Ocul Surf 2011;9(3):139
   PubMed Web of Science ®Google Scholar
• The Gallup Organization, Inc. The 2008 gallup study of dry eye sufferers. Multi-Sponsor Surveys, Inc; Princeton, NJ: 2008
   Google Scholar
• Jonisch J, Steiner A, Udell IJ. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea 2010;29(7):723-6
   PubMed Web of Science ®Google Scholar
• Foulks GN. Pharmacological management of dry eye in the elderly patient. Drugs Aging 2008;25:105-18
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase III Study Group. Ophthalmology 2000;107:631-9
   PubMed Web of Science ®Google Scholar
• Ridder WH III. Cyclosporine use in dry eye disease patients. Expert Opin Pharmacother 2008;9:3121-8
   PubMed Web of Science ®Google Scholar
• Aragona P, Di Peitro R. Is it safe to use topical NSAIDs for corneal sensitivity in Sjögren's syndrome patients? Expert Opin Drug Saf 2007;26:260-4
   Google Scholar
• Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011;30:308-14
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol 2011;89:e591-7
   PubMed Web of Science ®Google Scholar
• Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:336-56
   PubMedGoogle Scholar
• Committee PPP. American academy of ophthalmology cornea/external disease panel. Preferred Practice Patterns Committee; Dry eye syndrome San Francisco (CA): 2008
   Google Scholar
• Yen MT, Pflugfelder SC, Feuer WJ. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am J Ophthalmol 2001;131(3):314-23
   PubMed Web of Science ®Google Scholar
• Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23(8):762-70
   PubMed Web of Science ®Google Scholar
• Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf 2009;7(4):199-211
   PubMed Web of Science ®Google Scholar
• Viso E, Rodriguez-Ares MT, Abelenda D, et al. Prevalence of asymptomatic and symptomatic meibomian glanddysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 2012;53:2601-6
   PubMed Web of Science ®Google Scholar
• Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and managementof dry eye disease. Am J Ophthalmol 2011;151(5):792-798.e1
   PubMed Web of Science ®Google Scholar
• Enríquez-de-Salamanca A, Bonini S, Calonge M. Molecular and cellular biomarkers in dry eye disease and ocular allergy. Curr Opin Allergy Clin Immunol 2012;12(5):523-33
   PubMed Web of Science ®Google Scholar
• Lopin E, Deveney T, Asbell PA. Impression cytology: recent advances and applications in dry eye disease. Ocul Surf 2009;7(2):93-110
   PubMed Web of Science ®Google Scholar
• Sullivan BD, Crews LA, Sönmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea 2012;31(9):1000-8
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;4:4293-301
   Google Scholar
• Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009;147:198-205 e191
   PubMed Web of Science ®Google Scholar
• Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci 2007;48:2561-9
   PubMed Web of Science ®Google Scholar
• Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci 2009;50:3203-9
   PubMed Web of Science ®Google Scholar
• Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol 2009;2(4):375-6
   PubMed Web of Science ®Google Scholar
• Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol 2009;182:1247-52
   PubMed Web of Science ®Google Scholar
• de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol 2008;71(Suppl):89-95
   PubMedGoogle Scholar
• Corfield AP, Carrington SD, Hicks SJ, et al. Ocular mucins: purification, metabolism and functions. Prog Retin Eye Res 1997;16:627-56
   Web of Science ®Google Scholar
• Shigemitsu T, Shimizu Y, Ishiguro K. Mucin ophthalmic solution treatment of dry eye. Adv Exp Med Biol 2002;506:359-62
   PubMed Web of Science ®Google Scholar
• Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol 2005;243(6):531-8
   PubMed Web of Science ®Google Scholar
• Scaffidi RC, Korb DR. Comparison of the efficacy of two lipid emulsion eyedrops in increasing tear film lipid layer thickness. Eye Contact Lens 2007;33(1):38-44
   PubMedGoogle Scholar
• Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol 2011;5:783-90
   PubMedGoogle Scholar
• Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 2007;144:86-92
   PubMed Web of Science ®Google Scholar
• Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004;88:1467-74
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratoplasty. Ophthalmology 2004;111(6):1115-20
   PubMed Web of Science ®Google Scholar
• Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 2000;84(1):76-84
   PubMed Web of Science ®Google Scholar
• AUW-Haedrich C, Feltgen N. Estrogen receptor expression in meibomian glands and its correlation with age and dry-eye parameters. Graefes Arch Clin Exp Ophthalmol 2003;241(9):705-9
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Wickham LA, Rocha EM, et al. Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland. Adv Exp Med Biol 1998;438:11-42
   PubMed Web of Science ®Google Scholar
• Versura P, Campos EC. Menopause and dry eye. A possible relationship. Gynecol Endocrinol 2005;20(5):289-98
   PubMed Web of Science ®Google Scholar
• Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea 1998;17(4):353
   PubMed Web of Science ®Google Scholar
• Scuderi G, Contestabile MT, Gagliano C, et al. Effects of phytoestrogen supplementation in postmenopausal women with dry eye syndrome: a randomized clinical trial. Can J Ophthalmol 2012;47(6):489-92
   PubMed Web of Science ®Google Scholar
• Smith JA, Vitale S, Reed GF, et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol 2004;122(2):151-6
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv 2012;2012:604204
   PubMedGoogle Scholar
• Buggage RR, Amrane M, Ismail D, et al. The effect of Cyclokat® (Unpreserved 0.1% cyclosporine cationic emulsion) on corneal involvement in patients with moderate to severe dry eye disease participating in a Phase III, multicenter, randomized, controlled, double-masked, clinical trial. Eur J Ophthalmol 2011; published online 4/14/2011 11:07:01 AM; DOI:10.5301/EJO.2011.7544
   Google Scholar
• Serhan CN, Chiang N, van Dyke TE. Resolving inflammation: dual antiinflammation and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:347-61
   Google Scholar
• Arita M, Yoshida M, Hong S, et al. Resolvin E1 an endogenous lipid mediator derived from omegas-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005;102:7671-6
   PubMed Web of Science ®Google Scholar
• Gjörstrup P, Dubrovskiy A, Dodge D, et al. Resolvin E1 (RvE1) an endogenously formed immune modulator attenuates clinical signs of autoimmune disease in the Rat CIA model concurrent with inhibition of T-cell dependent cytokines in mixed cell populations from draining lymph nodes. Presented at: The Association for Research in Vision and Ophthalmology; May 3–7 2009; Fort Lauderdale, FL; A819
   Google Scholar
• Haworth O, Cernadas M, Yang R, et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9(8):873-9
   PubMed Web of Science ®Google Scholar
• Li N, He J, Scwartz CE, et al. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther 2010;26:431-9
   PubMed Web of Science ®Google Scholar
• de Paiva CS, Schwartz CE, Gjörstrup P, Pflugfelder SC. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea 2012;31(11):1299-303
   PubMed Web of Science ®Google Scholar
• Cortina MS, Bazan HE. Docosahexaenoic acid, protectins and dry eye. Curr Opin Clin Nutr Metab Care 2011;14(2):132-7
   PubMed Web of Science ®Google Scholar
• Murphy CJ, Bentley E, Miller PE, et al. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Invest Ophthalmol Vis Sci 2011;52(6):3174-80
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, et al. A Phase II randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012;153(6):1050-60
   PubMed Web of Science ®Google Scholar
• Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol 2011;5:633-43
   PubMedGoogle Scholar
• Güngör S, Delgado-Charro MB, Ruiz-Perez B, et al. Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J Controll Release 2010;147:225-3
   PubMed Web of Science ®Google Scholar
• Ruiz-Perez B, Dowie T, Gee R, et al. Transscleral delivery of a 12.4 kDa protein by ocular iontophoresis. Invest Ophthalmol Vis Sci 2008;49:1813-68
   Web of Science ®Google Scholar
• Bar-Yehuda S, Silverman MH, Kerns WD, et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007;16:1601-13
   PubMed Web of Science ®Google Scholar
• Mabley J, Soriano F, Pacher P, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5=-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003;466:323-9
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Rath-Wolfson L, Del Valle L, et al. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum 2009;60:3061-71
   PubMed Web of Science ®Google Scholar
• Lee HT, Kim M, Joo JD, et al. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006;291:R959-69
   PubMed Web of Science ®Google Scholar
• Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered CF101: data from a Phase II clinical trial. Ophthalmology 2010;117(7):1287-93
   PubMed Web of Science ®Google Scholar
• Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a Phase I/II trial. Ophthalmology 2012;119(7):1328-35
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 2012;31(8):945-9
   PubMed Web of Science ®Google Scholar
• Li Z, Choi W, Oh HJ, Yoon KC. Effectiveness of topical infliximab in a mouse model of experimental dry eye. Cornea 2012;31(Suppl 1):S25-31
   PubMed Web of Science ®Google Scholar
• Sosne G, Qiu P, Ousler GW III, et al. Thymosin β4: a potential novel dry eye therapy. Ann N Y Acad Sci 2012;1270:45-50
   PubMed Web of Science ®Google Scholar
• Lan W, Petznick A, Heryati S, et al. Nuclear Factor-κB: central regulator in ocular surface inflammation and diseases. Ocul Surf 2012;10(3):137-48
   PubMed Web of Science ®Google Scholar
• Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009;54:1500-7
   PubMed Web of Science ®Google Scholar
• Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 2004;23:613-19
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide Ophthalmic Suspension Phase II Study Group. N;Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled Phase II study. Ophthalmology 2012;119(12):2471-8
   PubMed Web of Science ®Google Scholar
• Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs 2004;13(1):47-54
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K; Diquafosol Ophthalmic Solution Phase II Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase II clinical trial. Ophthalmology 2012;119(10):1954-60
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tsubota K, Watanabe H, Ohashi Y. The safety and efficacy of long-term treatment with 3% diquafosol ophthalmic solution for dry eye. J Eye 2012;29:527-35
   Google Scholar
• Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye 2012;26(10):1363-8
   PubMed Web of Science ®Google Scholar
• Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry 2011;82(1):38-43
   PubMedGoogle Scholar
• Yamaguchi M, Kutsuna M, Maruo H, et al. Sustained effects of sodium hyaluronate solution on tear film stability evaluated by tear stability analysis system Nihon Ganka Gakkai Zasshi. 2011;115(2):134-41
   Google Scholar
• Dumbleton K, Woods C, Fonn D. An investigation of the efficacy of a novel ocular lubricant. Eye Contact Lens 2009;35:149-55
   PubMed Web of Science ®Google Scholar
• Baeyens V, Bron A, Baudouin C; Vismed/Hylovis Study Group. Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. J Fr Ophtalmol 2012;35(6):412-19
   PubMed Web of Science ®Google Scholar
• Dougherty J, McCulley J, Silvany R, Meyer D. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-5
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006;83:526-35
   PubMed Web of Science ®Google Scholar
• Shafaa MW, El Shazly LH, El Shazly AH, et al. Efficacy of topically applied liposome-bound tetracycline in the treatment of dry eye model. Vet Ophthalmol 2011;14(1):18-25
   PubMed Web of Science ®Google Scholar
• Veldman P, Colby K. Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness. Int Ophthalmol Clin 2011;51(4):43-52
   PubMedGoogle Scholar
• Nichols JJ, Bickle KM, Zink RC, et al. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Eye Contact Lens 2012;38(2):73-9
   PubMed Web of Science ®Google Scholar
• Urzua CA, Vasquez DH, Huidobro A, et al. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res 2012;37(8):684-8
   PubMed Web of Science ®Google Scholar
• Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Opthalmol 2005;139(2):242-6
   PubMed Web of Science ®Google Scholar
• Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea 2001;20:802-6
   PubMed Web of Science ®Google Scholar
• Cho YK, Huang W, Kim GY, Lim BS. Comparison of autologous serum eye drops with different diluents. Curr Eye Res 2013;38(1):9-17
   PubMed Web of Science ®Google Scholar
• Na KS, Kim MS. Allogenic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 2012;28(5):479-83
   PubMed Web of Science ®Google Scholar
• Versura P, Profazio V, Buzzi M, et al. Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 2013;32(4):412-18
   PubMed Web of Science ®Google Scholar
• Piwkumsribonruang N, Somboonporn W, Luanratanakorn P, et al. Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial. J Med Assoc Thai 2010;93(6):647-52
   PubMedGoogle Scholar
• Coksuer H, Ozcura F, Oghan F, et al. Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women. Climacteric 2011;14(4):482-7
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 2007;129:210-23
   PubMed Web of Science ®Google Scholar
• Pestka JJ. n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis. Prostaglandins Leukot Essent Fatty Acids 2010;82:251-8
   PubMed Web of Science ®Google Scholar
• Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008;52:885-97
   PubMed Web of Science ®Google Scholar